AHR and colon carcinoma: In the CT26 colon carcinoma syngeneic mouse model, AhR blockade with a potent antagonist as monotherapy enhanced T cell function, decreased M2-like macrophages infiltration and drove antitumor immune response in vivo, resulting in the inhibition of tumor formation (105).